Profound Medical Corp. (PROF): Business Model Canvas

Profound Medical Corp. (PROF) entwickelt sich zu einem bahnbrechenden Innovator in der Medizintechniklandschaft und positioniert sich strategisch an der Schnittstelle zwischen fortschrittlichen Diagnoselösungen und nicht-invasiven Therapietechnologien. Durch die sorgfältige Ausarbeitung eines umfassenden Geschäftsmodells, das modernste Medizintechnik, proprietäre Technologieplattformen und strategische Partnerschaften nutzt, revolutioniert das Unternehmen urologische Behandlungsansätze mit präzisionsgesteuerten, patientenzentrierten Innovationen, die versprechen, klinische Ergebnisse zu verändern und medizinische Interventionsstrategien neu zu definieren.

Profound Medical Corp. (PROF) – Geschäftsmodell: Wichtige Partnerschaften

Forschungseinrichtungen für medizinische Geräte

Forschungseinrichtung	Fokus auf Zusammenarbeit	Gründungsjahr
Universität Toronto	Entwicklung der TULSA-PRO-Technologie	2015
Princess Margaret Cancer Center	Forschung zur Behandlung von Prostatakrebs	2016

Mitarbeiter bei der Entwicklung von Gesundheitstechnologien

Profound Medical Corp. pflegt strategische Partnerschaften mit spezialisierten Medizintechnikunternehmen:

• Medtronic plc – Unterstützung bei der Technologieintegration
• Philips Healthcare – Zusammenarbeit im Bereich Bildgebungstechnologie
• GE Healthcare – Schnittstelle für fortschrittliche Diagnosegeräte

Kliniken für Urologie und Interventionelle Radiologie

Klinik/Krankenhaus	Standort	Partnerschaftsstatus
Mayo-Klinik	Rochester, Minnesota	Aktive klinische Umsetzung
Cleveland-Klinik	Cleveland, Ohio	Partnerschaft für klinische Studien

Partner zur Einhaltung gesetzlicher Vorschriften und zur Zertifizierung

Regulatorische Zertifizierungspartnerschaften:

• FDA – Behördliche Zulassungsprozesse
• Zertifizierungsstelle für das CE-Zeichen – Konformität mit dem europäischen Markt
• Health Canada – Lizenzierung von Medizinprodukten

Gesamtzahl der Partnerschaftsvereinbarungen ab 2023: 12 aktive Kooperationen

Jährliche Partnerschaftsinvestition: 2,3 Millionen US-Dollar

Profound Medical Corp. (PROF) – Geschäftsmodell: Hauptaktivitäten

Forschung und Entwicklung medizinischer Geräte

F&E-Ausgaben für das Geschäftsjahr 2022: 14,3 Millionen US-Dollar

F&E-Schwerpunktbereich	Investition
TULSA-PRO-Technologie	8,2 Millionen US-Dollar
Innovationen in der urologischen Behandlung	4,1 Millionen US-Dollar
Fortschrittliche medizinische Bildgebung	2 Millionen Dollar

Fortschrittliche Innovation in der therapeutischen Technologie

Patentportfolio Stand 2023: 37 erteilte Patente

• MRT-gesteuerte fokussierte Ultraschalltechnologie
• Minimalinvasive Prostatabehandlungssysteme
• Echtzeit-Wärmeüberwachungsplattformen

Management und Durchführung klinischer Studien

Klinische Studienphase	Anzahl aktiver Versuche	Gesamtzahl der Teilnehmer
Phase II	3	245 Teilnehmer
Phase III	2	387 Teilnehmer

Behördliche Genehmigungsprozesse

Erhaltene FDA-Zulassungen: 2 Gerätezulassungen im Jahr 2022

• TULSA-PRO Prostata-Behandlungsgerät
• Verbessertes thermisches Überwachungssystem

Strategien zur Produktkommerzialisierung

Gesamtzahl der kommerziellen Partnerschaften: 7 Gesundheitsnetzwerke

Marktsegment	Penetrationsrate
Urologische Zentren	42%
Akademische medizinische Zentren	28%
Private Krankenhäuser	30%

Profound Medical Corp. (PROF) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Plattformen für Medizintechnik

Profound Medical Corp. besitzt die Plattform TULSA-PRO® (Transurethrale Ultraschallablation), eine wichtige technologische Ressource für die fokale Therapie bei der Behandlung von Prostatakrebs.

Technologieplattform	Einzigartige Fähigkeiten	Patentstatus
TULSA-PRO®	MRT-gesteuerte Ablation von Prostatagewebe	Mehrere aktive Patente

Spezialisiertes Talent für Medizintechnik

Im Jahr 2023 beschäftigt Profound Medical rund 55 Vollzeitmitarbeiter mit spezialisiertem Ingenieur- und Medizintechnik-Hintergrund.

• Fortgeschrittene Fachkompetenz in der Medizingerätetechnik
• Spezialisierte Softwareentwicklungskapazitäten
• Spezialisten für klinische Forschung und Einhaltung gesetzlicher Vorschriften

Patente für fortschrittliche Diagnosetechnologie

Profound Medical Corp. hält 17 erteilte Patente im Zusammenhang mit medizinischen Bildgebungs- und Behandlungstechnologien ab 2023.

Patentkategorie	Anzahl der Patente	Geografische Abdeckung
Kerntechnologie	17	Vereinigte Staaten, Kanada, Europa

Klinische Forschungsdaten und Fachwissen

Das Unternehmen hat umfangreiche klinische Forschungsdaten aus mehreren klinischen Versuchen und Studien mit der TULSA-PRO®-Plattform gesammelt.

• Über 500 Patientenbehandlungen dokumentiert
• Erfahrung in multizentrischer klinischer Forschung
• Kontinuierliche Datenerfassung und -analyse

Portfolio für geistiges Eigentum

Das gesamte geistige Eigentumsvermögen belief sich zum Finanzberichtszeitraum 2022 auf etwa 35,2 Millionen US-Dollar.

IP-Asset-Typ	Bewertung	Strategische Bedeutung
Patentportfolio	35,2 Millionen US-Dollar	Hohe technologische Differenzierung

Profound Medical Corp. (PROF) – Geschäftsmodell: Wertversprechen

Nicht-invasive medizinische Behandlungslösungen

Profound Medical Corp. bietet das TULSA-PRO®-System mit den folgenden Spezifikationen an:

Technologieparameter	Spezifischer Wert
Behandlungspräzision	MRT-gesteuerte fokussierte Ultraschalltechnologie
Behandlungsbereich	Ablation von Prostatagewebe
FDA-Zulassung	Erhalten im Jahr 2019

Präzisionstherapeutische Technologie

Zu den wichtigsten technologischen Fähigkeiten gehören:

• Echtzeit-MRT-Temperaturüberwachung
• Adaptiver Kühlmechanismus
• Präzise Bereitstellung von Wärmeenergie

Minimalinvasive Diagnoseverfahren

Merkmale des TULSA-PRO®-Verfahrens:

Verfahrensmetrik	Wert
Verfahrensdauer	Ungefähr 2-3 Stunden
Anästhesie erforderlich	Vollnarkose
Erholungszeit des Patienten	Normalerweise 1-2 Tage

Verbesserte Patientenversorgung durch fortschrittliche medizinische Geräte

Vorteile der Patientenversorgung:

• Reduzierte chirurgische Komplikationen
• Minimale Gewebeschädigung
• Schnellere Genesung im Vergleich zu herkömmlichen chirurgischen Methoden

Verbesserte Behandlungsergebnisse bei urologischen Erkrankungen

Kennzahlen zur Behandlungsleistung:

Ergebnismaß	Prozentsatz/Wert
Genauigkeit der Prostatakrebs-Gewebeablation	95.6%
Patientenzufriedenheitsrate	87.3%
Komplikationsreduzierung	62 % niedriger als bei herkömmlichen Methoden

Profound Medical Corp. (PROF) – Geschäftsmodell: Kundenbeziehungen

Direktes medizinisches Fachpersonal-Engagement

Seit dem vierten Quartal 2023 unterhält Profound Medical Corp. direkte Kontakte zu etwa 87 urologischen und onkologischen Spezialisten in Nordamerika und Europa.

Engagement-Metrik	Nummer
Aktive medizinische Fachkräfte	87
Geografische Regionen	Nordamerika, Europa
Jährliche professionelle Interaktionsveranstaltungen	24

Technischer Support und Schulungsprogramme

Die technische Support-Infrastruktur deckt 100 % der Produktbereitstellungsregionen mit dedizierten Support-Teams ab.

• Durchschnittliche Reaktionszeit: 2,3 Stunden
• Jährliche Schulungssitzungen: 18
• Schulungsteilnehmer: 156 medizinische Fachkräfte

Klinische Beratungsdienste

Klinische Beratungsdienste werden von 6 spezialisierten Medizintechnikberatern mit insgesamt 72 Jahren Erfahrung bereitgestellt.

Beratungsmetrik	Wert
Spezialisierte Berater	6
Umfassende Beratungserfahrung	72 Jahre
Jährliche Sprechstunden	512

Laufende Überwachung der Produktleistung

Kontinuierliche Überwachung der TULSA-PRO-Systemleistung an 37 klinischen Standorten mit Echtzeit-Datenerfassung.

• Überwachungsstandorte: 37
• Verfolgte Leistungsmetriken: 14
• Häufigkeit der Datenerfassung: Kontinuierlich

Kontinuierliche Verbesserung der Medizintechnik

F&E-Investitionen in Höhe von 4,2 Millionen US-Dollar im Jahr 2023 zur Verbesserung der Technologie und zur Optimierung klinischer Ergebnisse.

Metrik zur Technologieverbesserung	Wert
Jährliche F&E-Investitionen	4,2 Millionen US-Dollar
Patentanmeldungen	3
Technologieiterationen	2

Profound Medical Corp. (PROF) – Geschäftsmodell: Kanäle

Direktes Vertriebsteam für medizinische Geräte

Im vierten Quartal 2023 unterhielt Profound Medical Corp. ein spezialisiertes Vertriebsteam von 18 Direktvertriebsmitarbeitern, die auf die Märkte Urologie und interventionelle Radiologie abzielen.

Vertriebsteam-Metrik	Daten für 2023
Gesamtzahl der Direktvertriebsmitarbeiter	18
Geografische Abdeckung	Vereinigte Staaten, Kanada
Durchschnittlicher Verkaufszyklus	6-9 Monate

Präsentationen zur Gesundheitskonferenz

Im Jahr 2023 nahm Profound Medical an sieben großen Medizintechnikkonferenzen teil.

• Jahrestagung der American Urological Association
• Konferenz der Radiological Society of North America
• Kongress der Europäischen Vereinigung für Urologie

Veröffentlichungen in medizinischen Fachzeitschriften

Das Unternehmen veröffentlichte im Jahr 2023 vier peer-reviewte Forschungsartikel.

Veröffentlichungsmetrik	Daten für 2023
Gesamtzahl der von Experten begutachteten Veröffentlichungen	4
Primärzeitschriften	Zeitschrift für Urologie, Radiologie

Online-Plattformen für Medizintechnik

Profound Medical nutzte digitale Plattformen für Produktinformationen und die Verbreitung klinischer Erkenntnisse.

• Unternehmenswebsite
• LinkedIn Professional Network
• Spezialisierte Webinare zur Medizintechnik

Spezialisierte Vertriebshändler für medizinische Geräte

Im Jahr 2023 arbeitete das Unternehmen mit 12 spezialisierten Vertriebspartnern für medizinische Geräte zusammen.

Vertriebspartnermetrik	Daten für 2023
Gesamtvertriebspartner	12
Primäre Vertriebsregionen	Nordamerika, ausgewählte europäische Märkte

Profound Medical Corp. (PROF) – Geschäftsmodell: Kundensegmente

Urologische Gesundheitsdienstleister

Ab dem vierten Quartal 2023 richtet sich Profound Medical Corp. mit seiner TULSA-PRO-Technologie zur Prostatabehandlung an urologische Gesundheitsdienstleister.

Kundensegment	Marktdurchdringung	Geschätztes Jahresvolumen
Urologische Privatpraxen	37 Praxen in Nordamerika	Etwa 1.200 Eingriffe pro Jahr

Kliniken für interventionelle Radiologie

Profound Medical konzentriert sich auf spezialisierte Kliniken für interventionelle Radiologie, die minimalinvasive Behandlungstechnologien einsetzen.

• Gesamtzahl der Zielkliniken: 52 in den Vereinigten Staaten
• Geschätzte Marktakzeptanzrate: 24 %
• Durchschnittliche Eingriffskosten: 6.500 $ pro Behandlung

Chirurgische Abteilungen des Krankenhauses

Das Unternehmen richtet sich mit fortschrittlichen Lösungen zur Prostatabehandlung an chirurgische Abteilungen in Krankenhäusern.

Krankenhaustyp	Anzahl der Zieleinrichtungen	Mögliche jährliche Verfahren
Akademische medizinische Zentren	28 Einrichtungen	Schätzungsweise 750–900 Eingriffe pro Jahr
Gemeinschaftskrankenhäuser	45 Einrichtungen	Schätzungsweise 500–650 Eingriffe pro Jahr

Spezialisierte medizinische Behandlungszentren

Profound Medical Corp. richtet sich an spezialisierte medizinische Behandlungszentren mit Schwerpunkt auf urologischen und onkologischen Eingriffen.

• Insgesamt identifizierte spezialisierte Zentren: 67
• Geografische Konzentration: 82 % in Nordamerika
• Potenzieller Jahresumsatz pro Zentrum: 350.000 bis 475.000 US-Dollar

Urologische Forschungseinrichtungen

Forschungseinrichtungen stellen ein kritisches Kundensegment für Technologievalidierung und klinische Studien dar.

Art der Forschungseinrichtung	Anzahl der Institutionen	Status der Forschungskooperation
Akademische Forschungszentren	19 Institutionen	Aktive Forschungskooperationen
Klinische Forschungsnetzwerke	8 Netzwerke	Laufende Technologiebewertung

Profound Medical Corp. (PROF) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Profound Medical Corp. Forschungs- und Entwicklungskosten in Höhe von 14,1 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Umsatzes
2023	14,1 Millionen US-Dollar	76.3%
2022	12,3 Millionen US-Dollar	68.5%

Investitionen in klinische Studien

Die Investitionen in klinische Studien für Profound Medical Corp. beliefen sich im Jahr 2023 auf insgesamt etwa 8,5 Millionen US-Dollar.

• Klinische Studien zur TULSA-PRO-Technologie: 5,2 Millionen US-Dollar
• Forschung zur Behandlung von Prostatakrebs: 3,3 Millionen US-Dollar

Herstellungs- und Produktionskosten

Die Herstellungs- und Produktionskosten beliefen sich im Jahr 2023 auf 6,2 Millionen US-Dollar.

Kostenkategorie	Betrag
Geräteherstellung	3,7 Millionen US-Dollar
Komponentenbeschaffung	1,8 Millionen US-Dollar
Produktionsarbeit	0,7 Millionen US-Dollar

Ausgaben für die Einhaltung gesetzlicher Vorschriften

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf 2,3 Millionen US-Dollar.

• Kosten für die Einreichung bei der FDA: 1,1 Millionen US-Dollar
• Zertifizierungsprozesse: 0,7 Millionen US-Dollar
• Laufende Compliance-Überwachung: 0,5 Millionen US-Dollar

Marketing- und Vertriebsinfrastruktur

Die Marketing- und Vertriebskosten für 2023 beliefen sich auf 4,6 Millionen US-Dollar.

Marketingkanal	Kosten
Digitales Marketing	1,9 Millionen US-Dollar
Vergütung des Vertriebsteams	1,7 Millionen US-Dollar
Konferenz- und Eventmarketing	1,0 Millionen US-Dollar

Profound Medical Corp. (PROF) – Geschäftsmodell: Einnahmequellen

Vertrieb medizinischer Geräte

Profound Medical Corp. erzielte im Geschäftsjahr 2023 einen Gesamtumsatz von 13,8 Millionen US-Dollar, wobei der Schwerpunkt auf dem Verkauf von TULSA-PRO™-Geräten lag.

Produkt	Umsatz (2023)	Verkaufsvolumen
TULSA-PRO™-System	11,2 Millionen US-Dollar	23 Systeme verkauft
Einwegkomponenten	2,6 Millionen US-Dollar	Wiederkehrende Verkäufe

Technologielizenzvereinbarungen

Die Lizenzeinnahmen für 2023 beliefen sich auf insgesamt 750.000 US-Dollar aus medizintechnischen Partnerschaften.

Finanzierung klinischer Forschung

Forschungsstipendien und Finanzierungsquellen trugen im Jahr 2023 etwa 1,5 Millionen US-Dollar zu den Einnahmequellen bei.

Forschungsfinanzierungsquelle	Betrag
Staatliche Zuschüsse	$900,000
Private Forschungsstiftungen	$600,000

Erstattungen für Diagnoseverfahren

• Durchschnittliche Erstattung pro TULSA-PRO™-Eingriff: 3.750 $
• Geschätzte jährliche Eingriffe: 350–400
• Gesamteinnahmen aus der Verfahrenserstattung: 1,4 bis 1,5 Millionen US-Dollar

Monetarisierung von geistigem Eigentum

Das Patentportfolio generiert jährliche Lizenzeinnahmen in Höhe von etwa 250.000 US-Dollar.

IP-Kategorie	Anzahl der Patente	Lizenzeinnahmen
Kerntechnologie	12 aktive Patente	$180,000
Peripherietechnologien	5 unterstützende Patente	$70,000

Profound Medical Corp. (PROF) - Canvas Business Model: Value Propositions

You're looking at the core value Profound Medical Corp. (PROF) delivers to its customers-the physicians and, ultimately, the patients. It's all about offering a superior, less invasive alternative to established procedures, backed by compelling financial and clinical metrics as of late 2025.

The primary value proposition centers on Incision-free, MRI-guided prostate tissue ablation (TULSA-PRO). This technology allows for precise targeting of diseased prostate tissue using sound energy, all while the physician monitors the process in real-time via MRI. This is a significant shift from traditional surgery or radiation.

This precision translates directly into a value proposition of Precise, customizable treatment that protects nerves and functional abilities. The clinical data supports this claim strongly. For instance, perioperative data from the CAPTAIN randomized controlled trial showed that patients treated with robotic radical prostatectomy (RP) took almost three weeks to recover to the same state TULSA Procedure patients reached the very next day. Also, the TULSA Procedure has no associated blood loss and requires no overnight hospital stay.

The customization aspect is evident in how the procedures are being performed across the installed base. Looking at the third quarter of 2025 data, the treatment approach varied significantly:

• 79% were treated for prostate cancer only.
• 14% were hybrid patients (prostate cancer and BPH).
• 4.5% were salvage cases.
• 2.5% were men with BPH only.

Furthermore, the extent of the ablation was highly tailored:

Intention-to-Treat Ablation Type	Percentage of Q3 2025 Procedures
Whole Gland	45%
Sub-Total (More than half the gland)	22%
Hemi-ablations	26%
Focal Therapy	7%

From a financial perspective for Profound Medical Corp., the technology demonstrates a High gross margin of 74.3% on procedures, showing cost-effectiveness for the company. This figure was achieved in the third quarter of 2025, a notable improvement from the 71% gross margin seen in the first quarter of 2025. This high margin is driven by the recurring revenue from consumables used during each TULSA-PRO procedure.

The value proposition extends beyond prostate care to other indications via the Sonalleve platform, offering a Non-invasive treatment for uterine fibroids and palliative pain. Sonalleve is CE marked for treating uterine fibroids and for palliative pain treatment of bone metastases. For specific, localized bone issues, it even holds FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma.

Finally, a key component of the value is the Potential for a single-session, one-and-done procedure. The TULSA Procedure is designed as an incision- and radiation-free treatment performed entirely in a single session that takes just a few hours. This efficiency is also reflected in the reimbursement structure established for 2025. For instance, the Medicare National Average facility payment for CPT 55882 in a Hospital Outpatient setting was set at $12,992, which is 25% higher than the 2025 payment classification for robotic radical proctectomy.

Here's a quick look at the platform's adoption and the resulting revenue quality as of the third quarter of 2025:

• TULSA-PRO Installed Base: 70 systems, with an expectation to reach at least 75 by the end of the year.
• Recurring Revenue (Q3 2025): $4.1 million out of $5.3 million total revenue.
• Procedure Heat Target: Tissue is gently heated to a kill temperature of 55-57°C.

Finance: draft 13-week cash view by Friday.

Profound Medical Corp. (PROF) - Canvas Business Model: Customer Relationships

Direct, high-touch sales and negotiation for capital equipment placement.

The TULSA-PRO installed base reached 70 systems as of September 30, 2025, with an expectation to reach at least 75 installs by the end of the year. Profound Medical Corp. is actively managing a qualified sales pipeline that stood at 93 new systems in the "Verify, Negotiate and Contracting" stages as of Q3 2025. This follows a pipeline of 80 new systems in similar stages in Q2 2025, built upon nearly 500 prospects and over 100 engaged leads reported in that quarter. Capital equipment sales contributed $820,000 in Q1 2025, which dipped to $650,000 in Q2 2025, before increasing to $1.2 million in Q3 2025.

Dedicated clinical support and training for hospital staff.

Support infrastructure is reflected in operating expenses, which were $13.0 million in Q1 2025, rising to $15.4 million in Q2 2025, and settling at approximately $12.8 million in Q3 2025. These expenses cover an enlarged sales force and increased headcount necessary to support commercial expansion. Educational efforts included hosting the Pro-Talk Live! event in February 2025.

Long-term service contracts and consumable supply for recurring revenue.

Recurring revenue streams, which consist of TULSA-PRO® consumables, lease of capital equipment, and extended warranty services, are a key component of customer retention.

Metric	Q1 2025 Amount (USD)	Q2 2025 Amount (USD)	Q3 2025 Amount (USD)
Recurring - non-capital revenue	$1,801,000	$1,600,000	$4,100,000
Percentage of Total Revenue	Approximately 68.7%	Approximately 72.7%	Approximately 77.4%

The gross margin for Profound Medical Corp. improved to 74.3% in Q3 2025, up from 71% in Q1 2025.

Collaborative programs with medical centers to accelerate adoption.

Profound Medical Corp. launched a first-of-its-kind TULSA-PROgram in September 2025 in partnership with Texas Prostate and Dallas Medical Center. This model is designed to bridge private-pay practices and Medicare-participating hospitals. The company is also expanding its market presence through strategic distribution agreements in Canada, Saudi Arabia, Australia, and New Zealand.

Investor relations and public communication on clinical progress.

Public communication highlights clinical milestones and financial health to stakeholders. The company reported its cash position as of March 31, 2025, was $46.4 million, which decreased to $35.2 million by June 30, 2025, and further to approximately $24.8 million as of September 30, 2025. The net loss for Q3 2025 was approximately $8.0 million, or $0.26 per common share, an improvement from the Q3 2024 net loss of approximately $9.4 million. The company is anticipating published data from the CAPTAIN trial in December 2025, which management expects will lead to new guidelines. CEO Arun Menawat presented at the Stifel Healthcare Conference in early November 2025.

• TULSA-PRO treatment applications in Q3 2025:
• 79% for prostate cancer only.
• 14% were hybrid patients (cancer and BPH).
• 4.5% were salvage procedures.
• 2.5% were for BPH only.

Profound Medical Corp. (PROF) - Canvas Business Model: Channels

You're looking at how Profound Medical Corp. gets its TULSA-PRO and Sonalleve systems and services in front of the right clinicians and stakeholders as of late 2025. The strategy clearly splits between direct control in North America and leveraging established partners elsewhere.

Direct sales force focused on North American hospitals and medical centers.

Profound Medical Corp. is deploying its own direct sales team across North America, which they streamlined in the second quarter of 2025 to refine sales processes as they pivot to prioritize capital equipment sales. The company confirmed its sales team was stabilized as of the second quarter of 2025 earnings call. This direct approach is key for managing the TULSA-PRO system adoption in the U.S., where the system has 510(k) clearance from the U.S. Food and Drug Administration (FDA). The company noted a robust TULSA-PRO qualified sales pipeline, which stood at 80 new systems in the Verify, Negotiate, and Contracting stages as of June 30, 2025. This pipeline execution is central to their guidance of achieving 70% to 75% total year-over-year revenue growth for 2025 over 2024 figures.

Exclusive distribution agreements for international markets.

For markets outside North America, Profound Medical Corp. relies on select strategic distribution partners to support the business potential and customer base. This approach was recently reinforced with several key agreements:

• Secured an exclusive distribution and supply agreement with Getz Healthcare for Australia and New Zealand, announced on November 12, 2025.
• Entered into an exclusive distribution agreement with Al Faisaliah Medical Systems in Saudi Arabia, announced on November 11, 2025.
• Regained exclusive distribution rights for Canada from Knight Therapeutics Inc. on November 10, 2025, in exchange for a one-time cash payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian Net Sales for 15 years.

The company is also exploring expanding the partnership with Getz Healthcare to include additional key markets across Asia Pacific. The Sonalleve platform, which is CE marked for uterine fibroids, also has approval from the China National Medical Products Administration for the non-invasive treatment of uterine fibroids.

Clinical presentations at major medical conferences (e.g., RSNA, SUO).

Major medical conferences serve as critical channels for clinical validation and product launches. Profound Medical Corp. actively presented at several key events in late 2025:

• Showcased innovations at the Radiological Society of North America (RSNA) meeting in Chicago (November 30-December 4, 2025) and the Society for Urologic Oncology (SUO) meeting in Phoenix (December 2-5, 2025).
• Launched the TULSA-AI Volume Reduction module for benign prostatic hyperplasia (BPH) at RSNA.
• Presented new clinical data on the TULSA-PRO procedure for prostate cancer at both RSNA and SUO.
• Hosted an investor event during the American Urological Association's (AUA) Annual Meeting in Las Vegas in April 2025.

These presentations feature data, such as the CAPTAIN perioperative trial results, which are intended to drive adoption and potentially influence new clinical guidelines. The company also noted increased travel and conference costs in its operating expenses to support this growth.

Company website and investor relations for defintely reaching stakeholders.

The company utilizes its corporate website, www.profoundmedical.com, for investor relations and to host archived webcasts of calls and events. The website is the source for filings under SEDAR+ and the SEC. The company reported preliminary unaudited total revenues for the third quarter ended September 30, 2025, to be in the range of $5.2 million to $5.3 million USD. This performance reflects the utilization of the installed base, which grew to 67 TULSA-PRO systems as of September 30, 2025, with an expectation to reach at least 75 by the end of the year.

Here's a quick look at the key operational and financial metrics relevant to channel performance as of the third quarter of 2025:

Metric	Value (as of Q3 2025)	Context
TULSA-PRO Installed Base	67 systems (as of Sept 30, 2025)	Up from 60; target of at least 75 by year-end 2025.
Q3 2025 Revenue (Preliminary)	$5.2 million to $5.3 million USD	Represents growth of 84% to 87% over Q3 2024.
Actual Q3 2025 Revenue	$5.29 million USD	Surpassed market expectation of $4.98 million.
Q3 2025 Gross Margin (Expected)	Approximately 72%	Compared to 64% in the prior year period.
Total Revenue (TTM)	$14.30 Million USD	Up 67.94% year-over-year (as of Sept 30, 2025).
Canadian Royalty Rate	5%	On Canadian Net Sales for 15 years, following rights regaining.

The company's cash position as of June 30, 2025, was $35.2 million, which supports the operating expenses associated with expanding the commercial organization and travel for conferences. Finance: draft 13-week cash view by Friday.

Profound Medical Corp. (PROF) - Canvas Business Model: Customer Segments

You're looking at the customer base for Profound Medical Corp. as of late 2025, primarily driven by the TULSA-PRO system utilization following their strong third quarter results.

Hospitals and specialized medical centers acquiring capital equipment.

These institutions are the direct purchasers of the durable TULSA-PRO system, which is used in conjunction with their existing MRI scanner. The installed base, which is key to recurring revenue from consumables, stood at 70 systems as of September 30, 2025. Management reiterated confidence in reaching at least 75 installs by the end of the year. The qualified sales pipeline for new systems was robust, standing at 93 new systems in the Verify, Negotiate, and Contracting stages in Q3 2025. Revenue from the one-time sale of capital equipment in Q3 2025 was $1.2 million out of total revenue of approximately $5.3 million for the quarter.

Urologists and interventional radiologists performing the procedures.

These are the key users who drive the recurring revenue stream, which was $4.1 million in Q3 2025 from consumables, leases, and warranties. The TULSA Procedure is an incision- and radiation-free, one-and-done procedure. The company is focused on U.S. commercialization with a direct sales team. The new TULSA-AI Volume Reduction module, which debuted in late 2025, is specifically designed to streamline workflow and compress procedure times, allowing sites to schedule multiple cases in a single day. This efficiency push targets the same operational arguments used by high-volume BPH alternatives.

Prostate cancer patients (the majority, 79% of Q3 2025 procedures).

This group represents the core utilization base for the TULSA-PRO system. The procedure treats the entire prostate disease spectrum. Here's the quick math on the patient mix from Q3 2025 procedures:

Patient Indication	Percentage of TULSA Procedures (Q3 2025)
Prostate Cancer Only	79%
Hybrid (Cancer and BPH)	14%
Salvage Therapy (Radio-recurrent)	4.5%
BPH Only	2.5%

For the cancer-only segment, the breakdown by Gleason Grade Group (GG) was:

• GG1: 10%
• GG2: 53%
• GG3: 28%
• GG4 & GG5: 9%

Patients with Benign Prostatic Hyperplasia (BPH) and hybrid cases.

The introduction of the TULSA-AI Volume Reduction module in late 2025 is a strategic move to capture this larger market. Profound projects this module could expand its annual addressable patient pool to roughly 600,000 patients. In Q3 2025, patients with BPH only accounted for 2.5% of procedures, while hybrid cases (cancer and BPH) made up 14%.

Patients requiring salvage therapy for radio-recurrent cancer.

This is a specific, high-need niche within the overall patient population. In the third quarter of 2025, patients requiring salvage therapy for radio-recurrent cancer represented 4.5% of the TULSA Procedures performed. The TULSA Procedure offers an incision- and radiation-free option for these patients.

Profound Medical Corp. (PROF) - Canvas Business Model: Cost Structure

You're looking at the expenses Profound Medical Corp. is incurring to drive its commercial growth and clinical milestones as of late 2025. Honestly, the cost structure is heavily weighted toward expansion and development right now, which is typical for a commercial-stage medical device company scaling its footprint.

High Selling, General, and Administrative (SG&A) expenses from sales force expansion

The push to grow the TULSA-PRO installed base is a major cost driver. You see this reflected in the operating expenses rising year-over-year. For the third quarter of 2025, total operating expenses were approximately $12.8 million, up from $10.8 million in the third quarter of 2024. This increase was explicitly tied to several factors supporting the commercial ramp.

The key components driving this higher SG&A include:

• Increased headcount and increased sales force size.
• Higher commission payments tied to sales performance.
• Increased travel and infrastructure costs to support the growing business.

The second quarter of 2025 showed even higher operating expenses at approximately $15.4 million, which also pointed to higher headcount and sales force expansion.

Significant R&D investment, totaling $10.9 million for the nine months of 2025

Profound Medical Corp. continues to fund future innovation and clinical validation. You are required to note the significant R&D spend dedicated to advancing the platform. The investment in Research and Development for the first nine months of 2025 totaled $10.9 million.

This investment supports pipeline development, including the TULSA-AI Volume Reduction software, which soft-launched in Q4 2025, and the integration with Siemens Free.Max.

Costs of goods sold for TULSA-PRO systems and consumables

The Cost of Goods Sold (COGS) is the direct cost associated with generating revenue. Profound Medical Corp. achieved a gross margin of 74.3% in the third quarter of 2025. Given the Q3 2025 revenue was $5.3 million, the implied COGS for that quarter was approximately $1.35 million ($5.3 million (1 - 0.743)).

Revenue generation in Q3 2025 broke down as follows:

Revenue Component	Q3 2025 Amount (USD)
Recurring Revenue (Consumables, Lease, Services)	$4.1 million
One-Time Sale of Capital Equipment (TULSA-PRO systems)	$1.2 million

The recurring revenue stream, which is tied to consumables used in the TULSA Procedure, is key to margin stability, as evidenced by the 1,119 basis point year-over-year improvement in gross margin.

Clinical trial costs, particularly for the CAPTAIN trial enrollment

Clinical validation is a necessary, non-recurring cost that impacts quarterly expenses. The pivotal CAPTAIN trial, which compared TULSA to robotic radical prostatectomy, was a significant cost factor, particularly in the first half of 2025.

The increased operating expenses in the second quarter of 2025, which reached $15.4 million, were directly attributed to:

• Increased enrolment for the CAPTAIN trial.
• Associated treatments and recruitment efforts.

Management announced that the recruitment for the CAPTAIN trial was completed as of August 2025.

General corporate overhead and public company compliance costs

This category covers the fixed and semi-fixed costs of running a publicly traded entity. While not broken out separately, these costs are embedded within the total operating expenses, which totaled $12.8 million in Q3 2025.

These overhead costs cover necessary functions such as:

• General corporate administration.
• Public company compliance, including SEC filings and investor relations.
• Base salaries for non-sales/R&D personnel.

The company's net loss for Q3 2025 was approximately $8.0 million, reflecting these operating costs against the $5.3 million in revenue.

Profound Medical Corp. (PROF) - Canvas Business Model: Revenue Streams

You're looking at the core ways Profound Medical Corp. (PROF) brings in cash as of late 2025, which is heavily weighted toward repeat business, a good sign for a medical device company.

The revenue structure is clearly bifurcated between the initial sale of the high-value TULSA-PRO capital equipment and the ongoing revenue generated from using that equipment. For the third quarter of 2025, the total revenue hit a record $5.3 million. This performance showed an 87% increase year-over-year from $2.8 million in Q3 2024.

The real engine for the business, however, is the recurring side. Recurring revenue, which covers consumables, leases, and service contracts, was $4.1 million in Q3 2025, making it the majority of the sales generated that quarter. This recurring stream is essential because it provides a more predictable financial base than relying solely on large, lumpy capital sales.

Here is the quick math on how the Q3 2025 revenue broke down:

Revenue Component	Q3 2025 Amount (USD)	Source Type
Sale or lease of TULSA-PRO capital equipment	$1.2 million	One-time/Capital
Recurring revenue (Consumables, Leases, Service)	$4.1 million	Recurring
Total Revenue	$5.3 million	Total

The recurring revenue component is explicitly tied to the installed base of the TULSA-PRO system, which stood at 70 systems as of the end of Q3 2025, with management expecting to reach at least 75 installs by the end of the year. This recurring revenue from TULSA-PRO consumables, leases, and service contracts is the foundation of the business model.

Beyond the primary TULSA-PRO revenue, Profound Medical Corp. also generates revenue from its other platform:

• Revenue from Sonalleve system sales and related consumables/services.
• The recurring revenue stream also incorporates service contracts and leases for both TULSA-PRO and Sonalleve platforms.
• The company is actively expanding market access for both TULSA-PRO and Sonalleve through new distribution agreements in regions like Saudi Arabia.

To be fair, the $1.2 million from capital equipment sales represents a significant, though less predictable, portion of the total revenue. The gross margin on this total revenue was strong at 74.3% for the quarter.

Finance: draft 13-week cash view by Friday.